Protecting Your Health Plan From High-Cost Therapies: A Hemgenix Example
Hemophilia is on the rise. In the 1990s, 1 in 5,000 males received a Hemophilia diagnosis at birth. Today, 1 […]
MaxorPlus
Blog, Maxor, MaxorPlus, Uncategorized
National Prescription Drug Takeback Day
On October 29th, 2022, The U.S. Drug Enforcement Agency is partnering with local law enforcement to provide the National Prescription
MaxorPlus, Press Releases
MaxorPlus wins Top Workplace for the second year in a row
TEMPE, Arizona, July 18, 2022 /PRNewswire/ — MaxorPlus has been named a Top Workplace for 2022 by The Arizona Top Workplaces for
Blog, Maxor, MaxorPlus
Women’s History Month Spotlight Series Pt. 1
Jennifer (Jen) Gallego, President, MaxorPlus This week we want to honor Jen Gallego, President of MaxorPlus, for Women’s History Month.
Maxor, Maxor Specialty, MaxorPlus
Maxor Webinar, “Specialty Pipeline Trends” by Sarah Richards and Jessie Heaton Available Now
MaxorPlus is hosting a 3 part webinar series, Understanding the Specialty Drug Pipeline for Emerging Business Models! In Part 1: Specialty
MaxorPlus, Press Releases
Az Central Names MaxorPlus A Winner Of The Arizona Top Workplaces 2021 Award
TEMPE, Ariz., July 12, 2021 /PRNewswire/ — MaxorPlus has been awarded a Top Workplaces 2021 honor by Arizona Top Workplaces Top Workplaces. The
MaxorPlus
Connect with MaxorPlus
At MaxorPlus, we connect members, clients, and partners to reduce costs and improve outcomes.
Maxor, MaxorPlus
International Women’s Day Spotlight
Meet Michelle Brisco-Fields, PharmD, MBA, MHA, MaxorPlus’ Vice President, Clinical Analytics and Clinical Product Development Who inspired you growing up
Kevin Krakowski joins MaxorPlus as Senior Vice President of Sales
Please welcome Kevin Krakowski to the MaxorPlus leadership team as our Senior Vice President of Sales where he will lead
Clinical News, Maxor, MaxorPlus
Connect to savings with MaxorPlus’ Care Improvement programs.
Our programs can help you achieve up to 5:1 ROI. How? Our clinical pharmacists and analytics team develop proprietary data